Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes
- 28 Downloads
To evaluate initial response and overall survival of neuroendocrine tumor (NET) liver metastases initially treated with transarterial embolization (TAE) using spherical particles of different sizes.
A single-institution retrospective review was performed of 160 patients with NET liver metastases initially treated with TAE using < 100 µm (n = 77) or only ≥ 100 µm (n = 83) spherical particles. For each patient, we evaluated: initial response by mRECIST, time to progression, overall survival, complications, primary site, tumor grade and degree of differentiation, volume of liver disease, extrahepatic disease, NET-related symptoms, comorbidities, Child–Pugh score, performance status, lobar versus selective embolization, and arteriovenous shunting.
Initial response was higher for TAE using particles < 100 versus TAE using only particles ≥ 100 μm (64 vs 42%, p = 0.007). Multivariate logistic regression showed that use of particles < 100 μm and liver < 50% replaced with tumor were independent predictors of a better initial response rate. There was no difference in major or minor complications between the two particle size groups. Median overall survival after TAE was 55 months for well- to moderately differentiated NET and 13 months for poorly differentiated or undifferentiated NET. There was no significant difference in survival between TAE patients treated with < 100 versus only ≥ 100-μm particles.
NET patients treated with TAE using particles < 100 μm had better initial response, but the same overall survival, compared to TAE using only particles ≥ 100 μm.
KeywordsNeuroendocrine tumor Carcinoid Transarterial embolization Particle size
This research was funded in part through an NIH/NCI Cancer Center Support Grant (P30 CA008748).
This research was funded in part through an NIH/NCI Cancer Center Support Grant (P30 CA008748). The funding source played no role in study design, data collection, data analysis, or writing the manuscript.
Compliance with Ethical Standards
Conflict of interest
FEB is a co-founder of Claripacs, LLC. He received research funding (investigator-initiated) and support for research meetings from Guerbet. He received research support (investigator-initiated) from GE. He received research supplies (investigator-initiated) from Bayer. He received a research grant and speaker fees from Society of Interventional Oncology, which were sponsored by Guerbet. He is an investor in Labdoor, Qventus, CloudMedx, and Notable Labs. AC is on the advisory board for Accurate Medical and is a stockholder in Amgen. EZ received an investigator-initiated industry research grant from Johnson & Johnson and has a pending investigator-initiated research grant from AAA-Novartis.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required. This HIPAA-compliant retrospective study was approved by the IRB.
For this type of study, informed consent is not required. This study has obtained IRB approval from Memorial Sloan Kettering Cancer Center, and the need for informed consent was waived.
- 1.NCCN clinical practice guidelines in oncology: neuroendocrine and adrenal tumors. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed 04 June 2018
- 10.Alexander ES, Soulen MC. Liver-directed therapies for neuroendocrine metastases. In: Cardona K, Maithel S, editors. Primary and metastatic liver tumors. Cham: Springer; 2018.Google Scholar
- 13.Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.CrossRefGoogle Scholar
- 14.Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159–71.CrossRefGoogle Scholar
- 18.Boas FE, Sofocleous CT. Embolotherapy for the management of liver malignancies other than hepatocellular carcinoma. In: Mauro MA, Murphy KPJ, Thomson K, Venbrux A, Morgan R, editors. Image-guided interventions. 3rd ed. Philadelphia: Elsevier; 2019.Google Scholar